United States

Profile: GlaxoSmithKline PLC (GSK.N)

GSK.N on New York Stock Exchange

24 Feb 2017
Change (% chg)

$0.07 (+0.17%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

GlaxoSmithKline plc (GSK), incorporated on December 6, 1999, is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK's principal pharmaceutical products include medicines in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

The Company's Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Company's Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Company's Vaccines business has a portfolio of over 30 pediatric, adolescent, adult and travel vaccines. The Company's Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Company's Consumer Healthcare business has a portfolio of brands, which include Sensodyne, Voltaren, Horlicks and Panadol.

The Company's Pharmaceuticals business focuses on the medicines in respiratory disease and human immunodeficiency virus (HIV). The Pharmaceuticals Research and Development (R&D) organization focuses on the discovery and development in several core areas of research, which include HIV and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases. The Company's HIV business is managed through ViiV Healthcare, which is engaged in antiretroviral medicines in clinical development. In addition to respiratory and HIV, it have a portfolio of other Pharmaceutical products for the treatment of conditions, such as lupus, benign prostatic hyperplasia, type 2 diabetes and bacterial infections. The Company has also have an Established Products Portfolio (EPP), which includes mature medicines in the areas of anti-infectives, allergy, central nervous system, dermatology, respiratory and urology.

The Company's Vaccines focus on the diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. The Company's Vaccines pipeline also focuses on malaria, HIV, Tuberculosis (TB) and Ebola. The Company's Vaccines portfolio has pediatric, adolescent, adult and travel vaccines that protect against approximately 21 different diseases, including hepatitis, influenza, pneumococcal disease, rotavirus and cervical cancer. The Company has approximately 15 candidate vaccines in development against diseases, including shingles, meningitis, RSV, Group B strep and chronic obstructive pulmonary disease (COPD) exacerbations.

The Company's medicines include Adartrel, Advair, Anectine, Argatroban, Atriance, Avandamet, Becotide, Betnovate, Combodart, Coreg, Flovent, Imigran, Lamictal, Mepron, Pentostam, Requip, Respontin nebules, Rythmol SR, Serevent, Staxyn, Tracrium, Treximet, Valtrex, Wellbutrin, Zinacef and Zovirax. The Company's vaccines include Bexsero, Cervarix, Fendrix, FluLaval (trivalent) & FluLaval (quadrivalent), Hepatyrix, Infanrix, Quinvaxem, Menjugate, Pandemrix, Priorix tetra, Rotarix, Twinrix and Typherix.

The Company's Consumer Healthcare business focuses on over the counter (OTC) medicines and fast moving consumer goods (FMCG) brands catering to healthcare, across its four categories of Wellness, Oral health, Nutrition and Skin health. The Company's Wellness products focus on respiratory, cold and flu, nasal decongestants, allergy, smoking cessation and pain management. Its Oral health focuses on sensitivity, acid erosion, denture care and gum health. Its Skin health focuses on treating cold sores and dry and sensitive skin. Its power brands include Voltaren, Panadol, Sensodyne, Theraflu, Otrivin, Parodontax and Poligrip. Its core brands include Tums, Flonase, Horlicks and Eno.

The Company's Pain Relief products include Voltaren, Panadol, Excedrin and Fenbid. Its Respiratory products include Theraflu, Otrivin, Flonase, Contac and Smokers' Health. Its Oral Health products include Sensodyne, Polident, Parodontax, Biotene and Aquafresh. Its Nutrition/Gastro Intestinal products include Horlicks, Eno and Tums. Its Skin Health products include Physiogel, Abreva, Zovirax, Lamisil and Fenistil.

The Company competes with Pfizer, Bayer, Johnson & Johnson, Merck, Reckitt Benckiser, Astra Zeneca, Sanofi, Hypermarca, Procter & Gamble, Carma Labs, Blistex Incorporated, Mondelez, Heinz, Colgate-Palmolive and Perrigo.

Company Address

GlaxoSmithKline PLC

980 Great West Road
P: +4420.80475000
F: +4420.80477807

Company Web Links